{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:17Z","timestamp":1772119277819,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen Science and Technology Program","award":["JCYJ20220530145001002"],"award-info":[{"award-number":["JCYJ20220530145001002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00467-025-06845-8","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:48:38Z","timestamp":1752572918000},"page":"3447-3457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective analysis of glucocorticoid therapy in pediatric immunoglobulin A nephropathy: Kidney outcomes and efficacy"],"prefix":"10.1007","volume":"40","author":[{"given":"Heyan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengkun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"6845_CR1","doi-asserted-by":"publisher","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","volume":"9","author":"T Moriyama","year":"2014","unstructured":"Moriyama T, Tanaka K, Iwasaki C et al (2014) Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 9:e91756. https:\/\/doi.org\/10.1371\/journal.pone.0091756","journal-title":"PLoS One"},{"key":"6845_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/s0022-3476(95)70027-7","volume":"127","author":"RJ Wyatt","year":"1995","unstructured":"Wyatt RJ, Kritchevsky SB, Woodford SY et al (1995) IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr 127:913\u2013919. https:\/\/doi.org\/10.1016\/s0022-3476(95)70027-7","journal-title":"J Pediatr"},{"key":"6845_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00467-007-0726-5","volume":"23","author":"N Yata","year":"2008","unstructured":"Yata N, Nakanishi K, Shima Y et al (2008) Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23:905\u2013912. https:\/\/doi.org\/10.1007\/s00467-007-0726-5","journal-title":"Pediatr Nephrol"},{"key":"6845_CR4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795\u20131803. https:\/\/doi.org\/10.1681\/ASN.2011050464","journal-title":"J Am Soc Nephrol"},{"key":"6845_CR5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","volume":"6","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Mani K, Swamy A et al (2021) Supportive management of IgA Nephropathy with renin-angiotensin blockade, the AIIMS primary IgA Nephropathy Cohort (APPROACH) Study. Kidney Int Rep 6:1661\u20131668. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.018","journal-title":"Kidney Int Rep"},{"key":"6845_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/s0272-6386(12)80031-x","volume":"21","author":"R Coppo","year":"1993","unstructured":"Coppo R, Amore A, Gianoglio B et al (1993) Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 21:593\u2013602. https:\/\/doi.org\/10.1016\/s0272-6386(12)80031-x","journal-title":"Am J Kidney Dis"},{"key":"6845_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10157-015-1195-y","volume":"20","author":"S Tanaka","year":"2016","unstructured":"Tanaka S, Ninomiya T, Katafuchi R et al (2016) The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy. Clin Exp Nephrol 20:689\u2013698. https:\/\/doi.org\/10.1007\/s10157-015-1195-y","journal-title":"Clin Exp Nephrol"},{"key":"6845_CR8","doi-asserted-by":"publisher","first-page":"CD003962","DOI":"10.1002\/14651858.CD003962.pub3","volume":"2","author":"DJ Tunnicliffe","year":"2024","unstructured":"Tunnicliffe DJ, Reid S, Craig JC et al (2024) Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2:CD003962. https:\/\/doi.org\/10.1002\/14651858.CD003962.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"6845_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825\u2013830. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007","journal-title":"Ann Intern Med"},{"key":"6845_CR10","first-page":"935","volume":"61","author":"Y Kobayashi","year":"1986","unstructured":"Kobayashi Y, Fujii K, Hiki Y et al (1986) Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med 61:935\u2013943","journal-title":"Q J Med"},{"key":"6845_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000184861","volume":"48","author":"Y Kobayashi","year":"1988","unstructured":"Kobayashi Y, Fujii K, Hiki Y et al (1988) Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 48:12\u201317. https:\/\/doi.org\/10.1159\/000184861","journal-title":"Nephron"},{"key":"6845_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883\u2013887. https:\/\/doi.org\/10.1016\/s0140-6736(98)03563-6","journal-title":"Lancet"},{"key":"6845_CR13","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus Immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1415463","journal-title":"N Engl J Med"},{"key":"6845_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432\u2013442. https:\/\/doi.org\/10.1001\/jama.2017.9362","journal-title":"JAMA"},{"key":"6845_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00467-016-3469-3","volume":"32","author":"R Coppo","year":"2017","unstructured":"Coppo R, Lofaro D, Camilla RR et al (2017) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32:139\u2013150","journal-title":"Pediatr Nephrol"},{"key":"6845_CR16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327:1888\u20131898. https:\/\/doi.org\/10.1001\/jama.2022.5368","journal-title":"JAMA"},{"key":"6845_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"6845_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12882-017-0637-z","volume":"18","author":"XH Chi","year":"2017","unstructured":"Chi XH, Li GP, Wang QS et al (2017) CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equation seems more suitable for Chinese patients with chronic kidney disease than other equations. BMC Nephrol 18:226. https:\/\/doi.org\/10.1186\/s12882-017-0637-z","journal-title":"BMC Nephrol"},{"issue":"4S","key":"6845_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"6845_CR20","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1093\/eurheartj\/ehac328","volume":"43","author":"G de Simone","year":"2022","unstructured":"de Simone G, Mancusi C, Hanssen H et al (2022) Hypertension in children and adolescents. Eur Heart J 43:3290\u20133301. https:\/\/doi.org\/10.1093\/eurheartj\/ehac328","journal-title":"Eur Heart J"},{"key":"6845_CR21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC et al (2017) Oxford Classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014\u20131021. https:\/\/doi.org\/10.1016\/j.kint.2017.02.003","journal-title":"Kidney Int"},{"key":"6845_CR22","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00467-020-04483-w","volume":"35","author":"Y Shima","year":"2020","unstructured":"Shima Y, Nakanishi K, Hama T et al (2020) Crescentic IgA nephropathy in children. Pediatr Nephrol 35:1005\u20131014. https:\/\/doi.org\/10.1007\/s00467-020-04483-w","journal-title":"Pediatr Nephrol"},{"key":"6845_CR23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","volume":"26","author":"V Tesar","year":"2015","unstructured":"Tesar V, Troyanov S, Bellur S et al (2015) Corticosteroids in IgA Nephropathy: a retrospective analysis from the VALIGA Study. J Am Soc Nephrol 26:2248\u20132258. https:\/\/doi.org\/10.1681\/ASN.2014070697","journal-title":"J Am Soc Nephrol"},{"key":"6845_CR24","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1001\/jama.2013.4208","volume":"309","author":"MM Mitsnefes","year":"2013","unstructured":"Mitsnefes MM, Laskin BL, Dahhou M et al (2013) Mortality risk among children initially treated with dialysis for end-stage kidney disease, 1990\u20132010. JAMA 309:1921\u20131929. https:\/\/doi.org\/10.1001\/jama.2013.4208","journal-title":"JAMA"},{"key":"6845_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00467-018-4189-7","volume":"35","author":"A Cambier","year":"2020","unstructured":"Cambier A, Boyer O, Deschenes G et al (2020) Steroid therapy in children with IgA nephropathy. Pediatr Nephrol 35:359\u2013366. https:\/\/doi.org\/10.1007\/s00467-018-4189-7","journal-title":"Pediatr Nephrol"},{"key":"6845_CR26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0","journal-title":"Lancet"},{"key":"6845_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarell","year":"2025","unstructured":"Vivarell M, Samuel S, Coppo R et al (2025) IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol 40:533\u2013569. https:\/\/doi.org\/10.1007\/s00467-024-06502-6","journal-title":"Pediatr Nephrol"},{"key":"6845_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10157-011-0415-3","volume":"15","author":"M Stangou","year":"2011","unstructured":"Stangou M, Ekonomidou D, Giamalis P et al (2011) Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol 15:373\u2013380. https:\/\/doi.org\/10.1007\/s10157-011-0415-3","journal-title":"Clin Exp Nephrol"},{"key":"6845_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40620-015-0248-3","volume":"29","author":"C Pozzi","year":"2016","unstructured":"Pozzi C (2016) Treatment of IgA nephropathy. J Nephrol 29:21\u201325. https:\/\/doi.org\/10.1007\/s40620-015-0248-3","journal-title":"J Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06845-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:12:08Z","timestamp":1759234328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06845-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6845"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06845-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5996564\/v1","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}